Sort   by:  
 Page size 
ProteomicsGlobal proteome and phosphoproteome alterations in 3rd generation EGFR TKI resistance reveal drug targets to circumvent resistance
Lung cancer continues to be the leading cause of cancer mortality worldwide. The treatment of lung cancer patients harboring mutant EGFR with orally administered EGFR TKIs has been a paradigm shift. Osimertinib and rociletinib are two 3rd generation irreversible EGFR TKIs targeting the EGFR T790M mu...
ORGANISM(S): Homo sapiens (Human) 
2021-03-11 | PXD020108 | Pride
Resistance mechanism Lung adenocarcinoma 3rd generation egfr tki 
UnknownMechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).
Not available
S-EPMC8562388 | biostudies-literature
UnknownEfficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Not available
S-EPMC7761809 | biostudies-literature
UnknownSpecifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation.
Not available
S-EPMC11533552 | biostudies-literature
UnknownHER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy.
Not available
S-EPMC8609241 | biostudies-literature
UnknownQuantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
Not available
S-EPMC7984720 | biostudies-literature
UnknownPrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up.
Not available
S-EPMC11379626 | biostudies-literature
UnknownEfficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Not available
S-EPMC4765101 | biostudies-literature
UnknownPreclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.
Not available
S-EPMC9023070 | biostudies-literature
UnknownEGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.
Not available
S-EPMC8988076 | biostudies-literature
Sort   by:  
 Page size